BioMedNewsBreaks – KBL Merger Corp. IV (NASDAQ: KBLM) Featured in Seeking Alpha Article Discussing ‘Blockbuster Year for SPACs’

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously announced the acquisition of 180 Life Sciences, was featured in a Seeking Alpha news article. The piece discussed a “blockbuster year for SPACs,” indicating that, to date, fiscal year 2020 has seen 127 SPAC IPOs collectively raise over $48.5 billion in proceeds. This represents significantly more than the previous ten years combined. The article covers the process of going public via a SPAC as a cost-effective way to complete a M&A deal in weeks instead of months, as well as an attractive vehicle for biotech companies through providing ready access to capital and much greater public visibility. Seeking Alpha revealed high expectations for the merger of 180 Life Sciences and KBLM before year end, which comes on the heels of successful SPAC mergers of Immatics N.V. (NASDAQ: IMTX) with Arya Sciences; Immunovant Inc. (NASDAQ: IMVT) with Health Sciences Acquisitions Corporation (in 2019); AdaptHealth Holdings (NASDAQ: AHCO) with DFB Healthcare Acquisitions (in 2019); and currently MultiPlan with Churchill Capital Corp III (NYSE: CCXXU). The piece also highlighted DraftKings Inc. (NASDAQ: DKNG) and Skillz (NYSE: FEAC) as large and successful SPACS of the year.

To view the full article, visit https://ibn.fm/9NxSY

About KBL Merger Corp. IV

KBL Merger Corp. is a blank check company that raised $115 million with the goal of identifying and acquiring a company with a strong value proposition mainly in the U.S. health care industry. KBL Merger Corp. focused on this industry due to its management’s deep experience in this large, growing segment of the U.S. economy. Marlene Krauss, MD is the CEO of KBL Merger Corp. This is Dr. Krauss’ fourth SPAC in the healthcare space. She has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACS. For more information, visit www.KBLMerger.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork